Genmab has announced that GlaxoSmithKline (GSK) entered into a patent settlement agreement with Genentech and City of Hope for Ofatumumab.
GSK is Genmab's development and commercial collaborator for the CD20 antibody of atumumab.
The dispute concerned two US patents issued to Genentech and City of Hope, which are due to expire in December 2018.
The settlement means that the pending court case will now be concluded.
No further terms of the settlement have not been disclosed.
The settlement is not expected to affect Genmab's financial guidance for 2012, the Genmab said.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/gsk-enters-into-patent-settlement-agreement-with-genentech-and-city-of-hope-270312
